Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases

Published:2020-12 Issue: Volume:2 Page:100034
ISSN:2666-6219
Container-title:Current Problems in Cancer: Case Reports
language:en
Short-container-title:Current Problems in Cancer: Case Reports

Author:

Higashiyama Nicole^ORCID,Nangia Julie^ORCID,Shafaee Maryam Nemati,Chen Nan^ORCID,Michael Binu Liz,Rimawi Mothaffar^ORCID,Hoyos Valentina^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study;Bachelot;Lancet Oncol.,2013

2. Activity of T-DM1 in Her2-positive breast cancer brain metastases;Bartsch;Clin. Exp. Metastasis,2015

3. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment and survival in patients from registHER;Brufsky;Clin. Cancer Res.,2011

4. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis;Diéras;J. Clin. Oncol.,2013

5. Prognostic factors for patients with liver metastases from breast cancer;Eichbaum;Breast Cancer Res. Treat.,2006

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term response to sequential anti-HER2 therapies including trastuzumab-deruxtecan in a patient with HER2-positive metastatic breast cancer with leptomeningeal metastases: a case report and review of the literature;Frontiers in Oncology;2024-01-10

2. Efficacy of Trastuzumab Deruxtecan in a Patient With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer With Acute Intracranial Hypertension Because of Brain Metastases;JCO Precision Oncology;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3